3349 — Cosmos Pharmaceutical Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesBalancedLarge CapHigh Flyer

Annual income statement for Cosmos Pharmaceutical, fiscal year end - May 31st, JPY millions except per share, conversion factor applied.

	2020 May 31st	2021 May 31st	2022 May 31st	2023 May 31st	2024 May 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Yuho
Standards:	—	—	JAS	JAS	JAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	684,403	726,424	755,414	827,697	964,989
Cost of Revenue
Gross Profit	134,984	145,111	151,448	168,718	188,306
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	656,470	694,706	725,696	797,882	934,143
Operating Profit	27,933	31,718	29,718	29,815	30,846
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	30,402	38,596	33,048	32,773	33,719
Provision for Income Taxes
Net Income After Taxes	21,435	27,157	23,156	23,798	24,454
Net Income Before Extraordinary Items
Net Income	21,435	27,157	23,156	23,798	24,454
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	21,435	27,156	23,155	23,797	24,454
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	281	318	291	303	314
Dividends per Share